NHWA: The innovative drug NH600001 emulsion injection is expected to file for NDA this year
On May 15th, NHWA stated on the interactive platform that the innovative drug NH600001 emulsion injection developed by the company has completed Phase III clinical trials and is expected to file for NDA this year, aiming for a quick market launch
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments